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ABSTRACT
While the presence of an inflammatory response in AD
(Alzheimer’s disease) is well known, the data on inflammation are conflicting, suggesting that inflammation either
attenuates pathology, exacerbates it or has no effect. Our
goal was to more fully characterize the inflammatory
response in APP (amyloid precursor protein) transgenic mice
with and without disease progression. In addition, we have
examined how anti-Ab (amyloid b-peptide) immunotherapy
alters this inflammatory response. We have used quantitative RT–PCR (reverse transcription–PCR) and protein analysis
to measure inflammatory responses ranging from proinflammatory to anti-inflammatory and repair factors in
transgenic mice that develop amyloid deposits only (APPSw)
and amyloid deposits with progression to tau pathology and
neuron loss [APPSw/NOS22/2 (nitric oxide synthase 22/2)].
We also examined tissues from previously published immunotherapy studies. These studies were a passive immunization
study in APPSw mice and an active vaccination study in
APPSw/NOS22/2 mice. Both studies have already been
shown to lower amyloid load and improve cognition. We
have found that amyloid deposition is associated with high
expression of alternative activation and acquired deactivation genes and low expression of pro-inflammatory genes,
whereas disease progression is associated with a mixed phenotype including increased levels of some classical activation
factors. Immunotherapy targeting amyloid deposition in
both mouse models resulted in decreased alternative

inflammatory markers and, in the case of passive immunization, a transient increase in pro-inflammatory markers.
Our results suggest that an alternative immune response
favours retention of amyloid deposits in the brain, and
switching away from this state by immunotherapy permits
removal of amyloid.
Key words: alternative activation, amyloid deposition,
immunotherapy, microglia, neuroinflammation.

INTRODUCTION

AD (Alzheimer’s disease) is defined pathologically by the
presence of amyloid plaques composed of aggregated Abs
(amyloid b-peptides) and NFTs (neurofibrillary tangles) composed of hyperphosphorylated and aggregated tau protein.
These primary AD pathologies are associated with ‘activated’
microglia and reactive astrocytes. It was this initial observation
of activated inflammatory cells surrounding the amyloid
plaques and NFTs that stimulated the interest in the role of
inflammation in AD. Subsequent studies demonstrated numerous pro-inflammatory immune factors in autopsied brains of
humans diagnosed with AD (McGeer et al., 1987; Walker et al.,
2001; Lue and Walker, 2002; Rogers et al., 2007). Despite
the body of data showing inflammation in AD, the precise
changes in inflammatory state and the impact of such changes
throughout the progression of AD are unknown.
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In the periphery, the inflammatory responses to stimuli are
much better understood than the brain. For instance, there
are variety of responses ranging from a true pro-inflammatory
response, termed classical inflammation, through to repair and
anti-inflammatory responses, termed alternative inflammation
(Martinez et al., 2009). Classical inflammation is characterized
by high expression of IL-1b (interleukin 1b), TNFa (tumour
necrosis factor a) and IL-6 and occurs following an acute
stimulus such as a stab wound, an acute infection or the
acute phase of an ischaemic attack. Alternative inflammation
is characterized by high levels of AG1 (arginase 1), IL-1
receptor antagonist, MR (mannose receptor) and IL-4. Finally, a
third major inflammatory state has been described that is
associated with an active down-regulation of inflammation,
termed acquired deactivation. This state is characterized by
high levels of TGFb (transforming growth factor b), SPHK1
(sphingosine kinase 1) and CD163 (reviewed by Colton, 2009).
Although well characterized in the periphery, it is unclear
whether the brain is capable of the full spectrum of the abovedescribed inflammatory responses. The goal of the current
study was to determine how inflammatory responses are both
driven by, and directly influence, amyloid deposition with and
without progression to tau pathology and neurodegeneration.
We have examined the expression of specific classical
inflammation, alternative inflammation and acquired deactivation
genes and, where possible, their proteins, in mouse models of
AD that show amyloid deposition only (APPSw) and amyloid
deposition accompanied by tau hyperphosphorylation and
aggregation and neuronal loss [APPSw/NOS22/2 (nitric oxide
synthase 22/2)]. In addition, we have examined brain tissues from
previously published anti-Ab immunotherapy studies to determine how this therapeutic approach alters the basal inflammatory
state of the brain (Wilcock et al., 2004a, 2009). Our results show
that, first, the brain is capable of generating a spectrum of
inflammatory responses much like those found in the periphery.
Secondly, our results suggest that amyloid deposition alone is
primarily associated with alternative inflammation. However,
when there is disease progression to tau pathology and neurodegeneration, there is expression of classical inflammatory
genes and acquired deactivation, as well as those for alternative
inflammation. Finally, immunotherapy results in a significant
decrease in expression of alternative inflammation genes, along
with a transient increase in classical inflammation genes. These
gene changes occur prior to the observation of significant
amyloid reductions, suggesting that inflammation may have a
causal role in the pathogenesis of AD, or at least in the progression of amyloid pathology.

before use in the experiments on assessment of inflammatory
status. APPSw and NOS22/2 mice (B6 129P2NOS2tau1Lau/J;
Jackson Labs) (Laubach et al., 1998) of the same age were used
as littermate controls. APPSw mice were also studied at 12 and
106 weeks of age. Animals were fed standard mouse chow
and housed under 12 h light/12 h dark cycles at 21 ˚C in an
approved barrier facility. The number of mice analysed ranged
from six to ten mice per data point and groups were composed
of approximately equal males and females.

Tissue processing/immunocytochemistry
All mice used in these studies were killed using a lethal dose
of anaesthesia using a mixture of ketamine/xylazine prior to
harvest of tissue according to Duke University IACUC approved
procedures and National Institutes of Health guidelines on
animal care. Maximum care was taken to minimize the number
of mice used and to alleviate any suffering. Mice were killed
followed by intracardial perfusion with 25 ml of normal PBS.
Brains were rapidly removed and bisected in the mid-sagittal
plane. One-half of the brain was immersion fixed in 4% PFA
(paraformaldehyde), while the other was snap-frozen in liquid
nitrogen and stored at 280 ˚C (for genotype studies and for the
active vaccination study), or dissected, frozen on solid CO2 and
stored at 280 ˚C (for the passive immunization study). Fixed
tissue was processed and 25 mm sections were collected
as described previously (Wilcock et al., 2004b, 2009). Freefloating immunohistochemistry was used to detect the
regional localization of MR. The percentage area occupied
by Ab-positive immunostain was measured as described previously (Wilcock et al., 2004a).

Quantitative real-time RT–PCR
(reverse transcription–PCR)
RNA was extracted from the frozen tissue using the
PerfectPure RNA tissue kit (5 Prime Inc.) and, subsequently,
cDNA produced using the high-capacity cDNA archive kit
(Applied Biosystems). Real-time PCR was performed using the
TaqMan Gene Expression assay kit (Applied Biosystems)
according to the manufacturer’s instructions and as previously described (Colton et al., 2006a). The genes examined
are shown in Table 1 and were normalized to 18S rRNA.
Normal WT (wild-type) mice served as the comparator and
fold changes were calculated using the 2(2DDCt) method
(Livak and Schmittgen, 2001).

Western–blot analysis

MATERIALS AND METHODS

Animals
The APPSw/NOS22/2 mouse strain was generated as described
previously (Colton et al., 2006b) and aged until 52–60 weeks
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Protein was extracted from pulverized brain powder and
quantified using the BCA (bicinchoninic acid) protein assay kit
(Thermo Scientific), according to manufacturer’s instructions.
Proteins (15 mg) from each lysate were run on a denaturing SDS/
4–20% PAGE gel. The gel was transferred on to a PVDF membrane, and Western-blot analyses were performed for AG1 [Santa
Cruz Biotechnology (catalogue no. sc-20150); 1:1000, stains
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Table 1

Identification of gene probes used in the experiments
Mouse gene

Ref Seq

Arg1/AG1
CD163
CAT2 (SLC7A2)
Chi3l3 (YM1)
IL1rn
IL-1b
MARCO
Mrc1
Nos2
Sphk2
TGFb
HO-1
IL-6
TNFa

NM_007482
NM_053094
NM_007514
NM_009892
NM_031167
NM_008361
NM_010766
Nm_008625
NM_010927
NM_203280
NM_011577
NM_010442
NM_031168
NM_013693

multiple bands in the 37–45 kDa range], TGFb [Cell Signaling
Technology (catalogue no. 3711); 1:1000, stains multiple bands in
the 25–45 kDa range] or b-actin [Santa Cruz Biotechnology (catalogue no. sc-1616); 1:1000]. The blots were stripped using Restore
stripping buffer (Thermo Scientific) and re-probed using the
above protocol with b-actin as loading control. Semi-quantitative
densitometry analysis was performed using the FluorChem Q (Cell
BioSciences). Individual densitometry values were normalized to
the b-actin densitometry value from the same sample.

Statistics
The significance of genotype- and treatment-specific changes
was analysed by the unpaired Student’s t test or ANOVA using
JMP 9 (SAS) or GraphPad Prism 4 (GraphPad).

Anti-Ab immunotherapy
Brain samples were taken from mice that had previously
undergone active vaccination with either human Ab-(1–42)
peptide or KLH (keyhole-limpet haemocyanin). All mice used
in the active vaccination study were aged 12 months and
then vaccinated four times over a 4-month period. Mice were
killed at 16 months of age. Amyloid loads and cognition
data from this vaccination study were published previously
(Wilcock et al., 2009) and are summarized in Table 2.
We also re-used brain samples from a passive immunization study. In this case previously harvested, frozen
hippocampi were taken from passively immunized APPSw
(Tg2576) mice. This study was previously published with
respect to the effects on amyloid load and cognition (Wilcock
et al., 2004a), and these results are also summarized in
Table 2. Here, 19-month-old APPSw mice were assigned
to one of the four groups, control antibody for 3 months
or anti-Ab antibody 2286 [antibody 2286, mouse monoclonal
anti-human Ab-(28–40) IgG1; Rinat Neuroscience Corporation] at a dose of 10 mg/kg intraperitoneal for 1 month,
2 months or 3 months (n54 mice/group). The start of treatment
was staggered such that all mice were killed at the same age.
In this manner, a time course of changes with passive immunization was generated. Age-matched control APPSw mice were
injected intraperitoneal with mouse monoclonal anti-Drosophila

amnesiac protein (AMN) IgG1 antibody (Rinat Neuroscience
Corporation) at a dose of 10 mg/kg for 3 months. In all cases,
tissue processing in vaccinated mice was the same as described
above for mice used in the inflammatory status experiments.

RESULTS

Mice with only amyloid pathology show an
alternative inflammatory response, while those
with disease progression show mixed alternative
and classical
Using quantitative real-time RT–PCR, we examined the differences in gene expression profiles between WT and NOS22/2 control mice that show no disease pathology, and mice that show
either amyloid deposition only (APPSw; Tg2576), or amyloid
deposition plus disease progression to tau pathology and
neuronal loss (APPSw/NOS22/2). Analysis of the brain pathology
of the mice used in the study has been previously published and
described in detail (Colton et al., 2006b; Wilcock et al., 2009)
and results are summarized in Table 2. Figure 1 shows the
relative change in mRNA for classical inflammatory markers (IL1b, TNFa, IL-6, MARCO and CAT2), alternative inflammatory
markers (YM1, AG1 and IL1rn) and acquired deactivation markers
(TGFb, SphK and HO-1) for our transgenic mice using agematched WT mice as the reference group. As previously shown,
NOS22/2 mice kept under barrier conditions do not deviate from
WT levels of inflammatory gene expression (Colton et al., 2006a).
In contrast, the APPSw mice at 12 months, an age when there is
amyloid pathology present in the brain, demonstrate inflammatory changes. In APPSw mice, we found little to no expression
of pro-inflammatory genes (Figure 1A). The most notable
classical inflammatory changes were small but statistically
significant increases in IL-1b, MARCO and CAT2 mRNA levels.
In contrast, gene expression levels for markers of immunosuppressive states (YM1, AG1, IL-1rn, TGFb and Sphk1) were
significantly increased compared with WT and NOS22/2 mice
(Figure 1B). To determine whether the lack of pro-inflammatory
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(Wilcock et al., 2009)
Reversed
No further loss
Down 50–60%
Decrease 85%
APPSw/NOS22/2 12–16

No change

n/a
n/a
Increase 4-fold
Decrease 60%
APPSw

Passive
immunization
Active
vaccination

19–22

Down ,30%
++
12–16
APPSw/NOS22/2
Non-treated

3172¡1072* (3) +++

Improved

(Hsiao et al., 1996; Colton et al.,
2006b; Wilcock et al., 2008,
2009)
(Colton et al., 2006b; Wilcock
and Colton, 2008; Wilcock
et al., 2009)
(Wilcock et al., 2004a; 2004b)
Decrease Y maze; increase latency
to platform (Morris water maze);
no change from NOS22/2 (RAWM)
Decrease (RAWM)
None
12–16
APPSw
Non-treated

662¡100 (5)

+

None

References
Cognition
Neuron loss
p-tau soma
CAA
Total Ab
(pg/ml)
Age
(months)
Mouse model
Study

Histopathological data

Summary of previously published data for mouse pathology and anti-Ab immunotherapy studies
Numbers in brackets are the number of mice. *P,0.05 compared with APPSw; CAA, cerebral amyloid angiopathy (vascular amyloid); RAWM, radial arm water maze.
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markers was due to the age of the APPSw mice, we also
measured mRNA changes for IL6, TNFa, IL-1b, CAT2 and MARCO
in 12- and 106-week-old control APPSw mice. No significant
statistical changes in mRNA levels were found in any
inflammatory marker in 12-week-old mice, but TNFa and HO-1
mRNA were slightly but significantly raised in 106-week-old
mice (see Supplementary Figure S1 available at http://www.
asnneuro.org/an/003/an003e069add.htm).
APPSw/NOS22/2 mice at 12 months show amyloid pathology, tau hyperphosphorylation, aggregation and redistribution
to neuronal soma as well as significant neuronal loss, therefore
representing a model of amyloid deposition with disease
progression (Colton et al., 2006b; Wilcock and Colton, 2008;
Wilcock et al., 2009). These APPSw/NOS22/2 mice showed a
shift in the immune phenotype from a predominately
alternative inflammation in the APPSw alone to a mixed
inflammatory state expressing both classical inflammation and
alternative inflammation. Classical inflammatory genes (IL-6,
IL-1b and CAT2) significantly increased compared with APPSw,
NOS22/2 or WT control mice. Expression of alternative inflammation and acquired deactivation genes such as YM1 and
AG1 was significantly lower in the APPSw/NOS22/2 compared
with APPSw mice, yet still elevated compared with NOS22/2
and WT mice. In contrast, expression of IL-1rn, SphK and HO-1
increased, while expression of TGFb remained at the same
elevated level observed in the APPSw mice. A mixed inflammatory state is consistent with chronic inflammatory disease
(Wynn, 2008) and is also seen in brains of humans with AD
(Colton et al., 2006a).
To determine whether protein levels were changed in a
manner consistent with the observed changes in mRNA, we
performed ELISAs and Western blottings where reliable antibodies were available. ELISA assays were performed for
TNFa and IL-6 on brain lysates from each of the mice used in
the study. As shown in Figure 2, the protein levels of IL-6
(Figure 2A) and TNFa (Figure 2B) were either unchanged
or slightly increased in APPSw mice compared with WT
and NOS22/2 mice. However, in APPSw/NOS22/2 mice, both
cytokines were significantly increased. TNFa protein levels increased approximately 200%, while IL-6 protein levels were
increased by approximately 80% over the values observed in
WT, NOS22/2 or APPSw mice. Semi-quantitative Western
blottings from whole brain lysates were used to measure
protein expression for AG1 and TGFb, characteristic proteins
for alternative inflammation and acquired deactivation
respectively. Typical blots for each of these proteins with their
corresponding density measurements are shown in Figure 3
and show similar patterns of changes as found in the
corresponding mRNA levels. AG1 levels were significantly
increased in APPSw but not in APPSw/NOS22/2 mice
compared with WT, while TGFb levels in both APPSw and
APPSw/NOS22/2 were increased compared with WT mice. The
increased TGFb levels were not significantly different between
APPSw and APPSw/NOS22/2 mice.
To this point, all data have been obtained on RNA and
protein extracts from whole-brain samples. We were
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Figure 2 Average protein levels for TNFa and IL-6
Means¡S.E.M. protein levels in whole brain lysates from 52–60-week-old
WT, NOS22/2, APPSw and APPSw/NOS22/2 mice were measured using
standard ELISA assays (n55–7 mice per strain). *P,0.05, ***P,0.001
compared with the NOS22/2 or WT control mice. ###P,0.001 compared
with the parent strain.

Figure 1 Comparison of mRNA expression levels for classical activation,
alternative activation and acquired deactivation genes associated with
the brain’s innate immune response between a mouse model of amyloid
deposition and a model of disease progression
Results represent the means¡S.E.M. fold-change in mRNA levels for classical
activation genes (A) and for alternative activation genes and acquired
deactivation genes (B) in 52–60-week-old NOS22/2, APPSw and APPSw/
NOS22/2 mice brain samples compared with WT control mice of the same
age (n55–7 mice per strain). *P,0.05, **P,0.01, ***P,0.001 compared with
the NOS22/2 control mice in each case. #P,0.05, ##P,0.01, ###P,0.001
compared with the parent strain.

interested in determining, where possible, potential regional
contributions to the overall gene expression profiles. To
achieve this, we measured gene expression for two genes that
are known to be localized to perivascular microglia, that is,
Mrc1 (mannose receptor C1 gene) and CD163 (Hb-haptoglobin
scavenger receptor gene) (Fabriek et al., 2005; Galea et al.,
2005; Borda et al., 2008; Hawkes and McLaurin, 2009).
Figure 4(A) shows the relative changes in mRNA prepared
from whole-brain samples for these genes in each of the
mouse strains used in the study. Mrc1 was significantly
increased in APPSw and in APPSw/NOS22/2 mice compared
with WT and NOS22/2, with no difference between APP
(amyloid precursor protein) models. CD163 was significantly
increased only in the APPSw/NOS22/2 compared with the
WT, NOS22/2 and APPSw. To determine whether changes in
MR protein expression could be observed in the perivascular
compartment, we performed immunohistochemistry on brain

sections from WT, NOS22/2, APPSw and APPSw/NOS22/2
mice aged 12 months. MR positive staining was localized to
the cerebrovasculature and resembled staining patterns
previously observed by Hawkes and McLaurin (2009). MRpositive cells were localized throughout the brain in all
sections examined (subiculum is shown as an example,
Figures 4B–4D). Interestingly, fine cellular processes were
also stained in the subiculum of the APPSw/NOS22/2 mice,
in addition to the intense staining around the cerebral blood
vessels, giving a ‘fuzzy’ appearance (Figure 4D). We did not
observe such staining in the APPSw or control mice.

Anti-Ab immunotherapy results in a shift in the
inflammatory state
Passive immunization is an approach in which monoclonal
antibodies are directly administered. We have examined gene
expression changes in a previously published passive
immunization study that showed the time course of Ab
reductions (Table 2 summarizes previously published data).
Briefly, APPSw mice received weekly immunizations of antiAb antibody for 1, 2 or 3 months with the start age staggered
such that all mice were killed at 22 months of age. As shown
in the previously published data for this study, Ab levels
remained high after 1 month of treatment, but significantly
decreased after 2 and 3 months of treatment. These changes
are illustrated in Figure 5(A). To determine the effect that
immunotherapy has on the inflammatory state, we measured
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A similar analysis was performed for mice that had
undergone active vaccination where mice develop anti-Ab
antibodies as a result of immunogen injection, in this case,
vaccination with Ab42. We have previously published the
results of this active vaccination study with respect to
changes in Ab, tau, neuronal loss and cognition, and these
data are also summarized in Table 2. Briefly, we vaccinated
12-month-old APPSw/NOS22/2 mice four times over a 4month period, which resulted in an 85% reduction in brain
Ab deposition, as well as the prevention of neuron loss and a
50% decrease in phospho-tau levels. We have now examined
gene expression changes associated with classical inflammation, alternative inflammation and acquired deactivation
in samples of these mice brains. Vaccinated APPSw/NOS22/2
mice showed significant reductions in TNFa and IL-6 mRNA
compared with control vaccinated APPSw/NOS22/2 mice, yet
TNFa and IL-6 mRNAs were still significantly increased compared with WT and NOS22/2 mice (Figure 6A). Interestingly,
alternative inflammatory genes YM1 and AG1 were significantly reduced, not only compared with control vaccinated
APPSw/NOS22/2 but also compared with WT and NOS22/2
mice (Figure 6B). In addition, TGFb was reduced approximately to WT levels following vaccination (Figure 6B).
Inflammatory genes Mrc1 and CD163, known to be restricted
to the cerebrovasculature, decreased compared with both control
vaccinated APPSw/NOS22/2 mice, and WT mice (Figure 6C).

DISCUSSION
Figure 3 Western-blot analysis of AG1 and TGFb protein levels
Western blottings were performed using whole-brain lysates and the relative band
density of each antigen compared with b-actin was calculated for AG1 and for
TGFb. All band intensities were measured using the FluorChem Q (Cell Biosciences).
Lanes 1–3, WT; lanes 4–6, APPSw; lanes 7–9, APPSw/NOS22/2; *P,0.05 compared
with the WT2/2 control mice; #P,0.05 compared with the parent strain.

gene expression changes in the hippocampus for classical
inflammation (Figure 5B), alternative inflammation and
acquired deactivation (Figure 5C). Interestingly, significant
changes in the inflammatory state occurred prior to any
change in Ab levels. Following 1 month of treatment, classical
inflammatory genes IL-6 and TNFa were significantly
increased compared with APPSw mice receiving control
immunotherapy (Figure 5B). In contrast, 1 month after the treatment, alternative inflammatory genes YM1 and AG1, normally
high in APPSw mice, were significantly reduced compared with
APPSw mice receiving control immunotherapy (Figure 5C). The
most dramatic change was in AG1, where the expression actually
decreased significantly compared with WT mice. The acquired
deactivation genes Sphk1 and TGFb were significantly increased
after 1 month of treatment and continued to increase over the
2- and 3-month treatment periods (Figure 5C). While most gene
changes remained for the 2- and 3-month treatment periods, IL6 mRNA levels declined in comparison with the 1 month time
point (Figure 5B).
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Although inflammation has long been considered as an
important factor in the neurodegenerative process (Schwab
and McGeer, 2008; Rivest, 2009; Cameron and Landreth,
2010; Glass et al., 2010) the exact role of inflammation in
neurodegeneration is not yet fully understood. A commonly
held view is that amyloid deposition results in an inflammatory response that generates a toxic state leading to
neuronal damage and death and, ultimately, contributing
to the progression of degeneration. Much of the supporting
data for this hypothesis has originated from studies using in
vitro cultured cells or brain slices, or in vivo modelling of
acute inflammatory responses using agents such as LPS
(lipopolysaccharide) (Klegeris et al., 1994; Hu et al., 1995;
Meda et al., 1999; Colton et al., 2000; Lee et al., 2002; Block
and Hong, 2005; Bernardino et al., 2008). While acute
approaches have been useful, the disparate data that have
resulted from these types of studies have been difficult to
resolve (Abbas et al., 2002; Quinn et al., 2003; Malm et al.,
2006; Shaftel et al., 2007; Nichol et al., 2008). These data can
be explained somewhat by variations in experimental design,
mouse models and even differences in background strains
of mice. However, there is a clear need for a better understanding of the relationship between inflammatory state and
neurodegenerative processes. In the present study, we have

E 2011 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.

Immunotherapy modulates brain inflammation

Figure 4

Changes in expression for MR and CD163
(A) The average relative change in mRNA was determined using quantitative RT–PCR for MR (Mrc1) and the hemoglobin-haptaglobin
scavenger receptor (CD163) for NOS22/2 (N), APPSw (A) and APPSw/NOS22/2 (AN) mice (n55–7 mice per strain). **P,0.01
compared with the NOS22/2 control. ##P,0.01 compared with the parent strain. (B–D) Immunostained sections for MR in NOS22/2
(B; magnification 620; scale bar5500 mm) and in APPSw/NOS22/2 mice at low (C; magnification 620; scale bar5500 mm) and at
higher magnification (D; 640; scale bar5100 mm).

examined a broad spectrum of inflammatory markers that
represent three different inflammatory states: classical
inflammation, alternative inflammation and acquired deactivation. Each of these states have been shown, both in the
periphery and in the CNS (central nervous system), to have
very different consequences to disease process. We had
several goals for this study. The first goal was to better
establish markers for each inflammatory state and determine
their expression in the brain. The second goal was to
determine how these states are expressed in a mouse model
of amyloid deposition (APPSw) and a mouse model of amyloid
deposition with disease progression to tau pathology and
neuron loss (APPSw/NOS22/2). Finally, our third goal was to
determine how anti-Ab immunotherapy, an approach
currently in clinical trials for the treatment of AD and is
known to reduce Ab levels in the brain, affects the
inflammatory state.
We have examined markers of three distinct inflammatory
states (Gordon, 2003; Ransohoff and Perry, 2009; Perry et al.,
2010). Classical inflammation is characterized by increased
expression of TNFa, IL-1b and IL-6 and is commonly associated
with a pro-inflammatory, cellular toxicity response. However,
it is important to note that these markers can be also increased
in response to immune complexes or other induction signals,
and do not necessarily lead to toxicity. Alternative inflammation is characterized by high expression levels of the
genes YM1, AG1, Mrc1 and IL-1rn and is stimulated by antiinflammatory factors such as IL-4 and IL-13. While many of
these genes are considered ‘repair’ genes involved in matrix
restructuring and tissue repair, as well as the down-regulation
of the classical inflammatory response, their effects may not be
fully beneficial. Finally, acquired deactivation is characterized
by high TGFb, Sphk1 and HO-1 gene expression levels. This

inflammatory state can be directly stimulated by glucocorticoids or apoptotic cells, is immunosuppressive and actively
lowers the ability to mount a classical inflammatory response
(Ransohoff and Perry, 2009; Cameron and Landreth, 2010;
Colton and Wilcock, 2010).
Our data show that amyloid deposition, in the absence of
tau pathology and neuronal loss, results in a polarization to
alternative inflammation and acquired deactivation, as
opposed to the classical inflammation that is commonly
considered to be present. This polarization in the APPSw
mouse model is characterized by high expression levels of
alternative inflammation mRNA for YM1, AG1 and IL-1rn,
which were anywhere from 2.5- to more than 5-fold
increased compared with WT and NOS22/2 mice at 12 months
of age. This time period is clearly associated with elevated
Ab40 and Ab42 levels and amyloid deposition (Jacobsen
et al., 2006). Interestingly, in 3-month-old APPSw mice where
Ab levels remain below levels of detection (Jacobsen et al.,
2006), no changes in alternative activation genes were
observed. In contrast, we found that classical inflammation
genes TNFa, IL-6 and IL-1b were only marginally increased in
12-month-old APPSw mice, if at all, compared with WT and
NOS22/2 mice. In addition, acquired deactivation genes
TGFb, Sphk1 and HO-1 were also increased compared with
WT and NOS22/2 mice. Based on the current knowledge of
the function of the corresponding proteins, the brain’s
immune phenotype found in the APPSw mice is more likely
to be associated with matrix restructuring and downregulation of classical inflammatory signalling rather than
toxicity (Gordon, 2003; Colton, 2009). It is important to
point out that our data do not identify a specific cell type
involved in this immune process. Although AGI and YM1 and
their proteins have been clearly identified in microglia, these
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Figure 5 Passive immunization alters the immune profile in APPSw mice
(A) Parenchymal amyloid load in the cortex and hippocampus. As described in
the Materials and methods section, 19-month-old APPSw mice were assigned
to one of four groups, control antibody for 3 months or anti-Ab antibody
2286 (Rinat Neurosciences) for 1, 2 or 3 months (n54/group). The start of
dosing was staggered such that all mice were of the same age when killed.
The level of amyloid immunostain in brains from passively immunized APPSw
mice was measured by image analysis of immunostained regions as described
in the Materials and methods section. Results are presented as the means
¡S.E.M. of the % immunoreactive area. (B, C) Results represent the
means¡S.E.M. fold-change in mRNA levels for selected classical activation
genes (B) and for alternative activation and acquired deactivation genes (C)
in immunized compared with control mice starting at 9 months of age (n54
mice/group). *P,0.05, **P,0.01, ***P,0.001 compared with control mice.

genes are also expressed by neurons and/or astrocytes
(Braissant et al., 1999; Junker et al., 2005; Colton et al.,
2006a; Ponomarev et al., 2007). Interestingly, Ch3L1
(chitinase-3-like-1; also known as YKL40), which is a close
relative of Ch3L3 (the human equivalent of YM1) has been
recently shown to increase in CSF (cerebrospinal fluid) in
patients with early MCI (mild cognitive impairment) (CraigSchapiro et al., 2010). Multiple factors including restricted
regional expression or age may have also contributed to the
immune polarization observed in the APPSw mice. To better
understand the effects of age, we also measured mRNAs for
inflammatory genes in 12- and 106-week-old APPsw mice.
Pro-inflammatory gene expression did not change compared
with littermate WT mice in young mice, while only TNFa and
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Figure 6 Active immunization alters the immune profile in APPSw/
NOS22/2 mice
Mice were immunized with either Ab-(1–42) or KLH at 12 months of age
as described in the Materials and methods section and compared with
age-matched NOS22/2 mice immunized in a similar fashion. (A, B) Results
represent the means¡S.E.M. fold-change in mRNA levels for selected
classical activation genes (A) and for selected alternative activation and
acquired deactivation genes (B) in APPSw/NOS22/2 mice. (C) mRNA for
alternative activation genes (Mrc1; CD163) associated with the cerebrovasculature (n55–7 mice/group in all cases). **P,0.01, ***P,0.001 compared
with control mice. #P,0.05, ##P,0.01 compared with the Ab42 immunized
condition in each case.

HO-1 mRNAs were slightly elevated in the very old APPSw
mice. These data further support the idea that amyloid
deposition in the absence of extensive disease progression
may be associated with immunosuppression rather than
overt toxicity.
The inflammatory profile of the APPSw/NOS22/2 mouse
model that shows amyloid deposition with disease progression
to tau pathology and neuron loss is clearly different from the
profile observed in the APPSw mice alone. The main difference
is that, in addition to high alternative inflammation and
acquired deactivation, the APPSw/NOS22/2 mice now have
increased expression of classical inflammation genes. Therefore
these mice truly show a full spectrum of the inflammatory
states. As previously published, APPSw/NOS22/2 mice show a
30% hippocampal neuron loss at 54 weeks of age (Wilcock
et al., 2009). The presence of high classical inflammation may,
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indeed, be directly or indirectly related to this neurotoxicity.
Also, the increase in acquired deactivation genes in APPSw/
NOS22/2 mice compared with the APPSw mice may be
explained by the presence of these apoptotic neurons, a known
initiator of the acquired deactivation response.
We were interested in the relationship between Ab and
inflammatory state. Therefore we examined brain samples from
a previously published anti-Ab immunotherapy study for
changes in the inflammatory state. We found that immunotherapy, whether active vaccination or passive immunization,
or whether in APPSw or APPSw/NOS22/2 mice, significantly
reduced the expression of alternative inflammatory markers.
The time course study in passively immunized APPSw mice
clearly showed that the decrease in YM1 and AG1 preceded the
fall in Ab levels in the brain and was concomitant with an
increase in classical inflammation genes, both of which
occurred after only 1 month of treatment. Active vaccination
in APPSw/NOS22/2 mice showed that classical inflammation was decreased compared with control vaccinated APPSw/
NOS22/2 mice, but remained higher compared with WT
and NOS22/2 mice. The classical inflammation data may
appear to be contradictory between the two studies; however,
there are several important points to be considered. First,
APPSw mice alone do not express high levels of classical
inflammation genes, thus, any increase due to immunotherapy
represents a dramatic change in level. In contrast, APPSw/
NOS22/2 mice initially have elevated classical inflammation.
Our data show that although vaccination lowered mRNA levels,
the final levels were still higher than that found in normal mice.
However, the single most important point from this data is that
these dramatic shifts in the inflammatory state correspond to
significant changes in brain Ab levels and, as shown for passive
immunization, occurs prior to the reduction in Ab. Therefore
there is likely a causal relationship between inflammation and
Ab deposition.
The change in inflammatory state due to immunotherapy, and
its effect in lowering Ab, is not necessarily surprising. Several
reports demonstrate that intracranial injection of LPS, an agent
known to induce classical inflammation, results in the removal of
brain Ab in APP transgenic mice (Herber et al., 2007; Morgan,
2009; Chakrabarty et al., 2010). Also, we have previously shown
that microglial activation is not only associated with Ab removal
following intracranial injection of anti-Ab antibodies, but in
fact facilitates this removal (Wilcock et al., 2003). One potential
mechanism for such an effect is an increase in proteolytic
degradation of parenchymal Ab. Wilcock et al. (2011) have
recently demonstrated that the ratio of MMP (matrix metalloprotease) to TIMP (tissue inhibitor of MMP) is altered by Ab
immunotherapy. The present study demonstrates the overall
importance of the down-regulation of alternative inflammation
and the up-regulation of classical inflammation in changing
brain Ab levels. Our results suggest that amyloid deposition
results in a strong polarization of the inflammatory response to
alternative inflammation and, to a lesser extent, acquired
deactivation. When amyloid pathology is present exclusively,
very little classical inflammation is present. When disease

progression occurs in the APPSw/NOS22/2 mice to now show
tau pathology and neuron loss, there is a classical inflammatory response in addition to the alternative inflammation and
acquired deactivation. It is unclear at present whether the
classical inflammation causes the disease progression or whether
the opposite is true. Future studies will focus on these
pathways to determine the exact role. Clearly, there is a
beneficial role for classical inflammation; however, since antiAb immunotherapy increases classical inflammation and this
effect leads to the reduction of brain Ab. In addition, this
response does not necessarily result in toxicity, as no neuron
loss or cognitive deficit is observed in APPSw mice that are
passively immunized, including the mice examined in the
current study.
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